1. Home
  2. AAL vs IBRX Comparison

AAL vs IBRX Comparison

Compare AAL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Airlines Group Inc.

AAL

American Airlines Group Inc.

N/A

Current Price

$12.99

Market Cap

9.6B

ML Signal

N/A

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$6.64

Market Cap

8.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AAL
IBRX
Founded
1930
2014
Country
United States
United States
Employees
133700
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.2B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
AAL
IBRX
Price
$12.99
$6.64
Analyst Decision
Buy
Strong Buy
Analyst Count
25
4
Target Price
★ $15.40
$14.25
AVG Volume (30 Days)
★ 57.6M
12.0M
Earning Date
10-22-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.71
EPS
★ N/A
N/A
Revenue
★ $54,633,000,000.00
$113,288,000.00
Revenue This Year
$17.05
$99.98
Revenue Next Year
$6.71
$108.29
P/E Ratio
★ N/A
N/A
Revenue Growth
0.78
★ 668.31
52 Week Low
$10.09
$1.95
52 Week High
$18.79
$12.43

Technical Indicators

Market Signals
Indicator
AAL
IBRX
Relative Strength Index (RSI) 48.54 40.20
Support Level $11.59 N/A
Resistance Level $13.16 $8.62
Average True Range (ATR) 0.50 0.57
MACD -0.02 -0.16
Stochastic Oscillator 34.13 27.59

Price Performance

Historical Comparison
AAL
IBRX

About AAL American Airlines Group Inc.

American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: